These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Chylothorax and chylous ascites due to malignant lymphoma. Oosterbosch L; Leloup A; Verstraeten P; Jordens P Acta Clin Belg; 1995; 50(1):20-4. PubMed ID: 7725834 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380 [TBL] [Abstract][Full Text] [Related]
7. Progress and challenges in RET-targeted cancer therapy. Hu X; Khatri U; Shen T; Wu J Front Med; 2023 Apr; 17(2):207-219. PubMed ID: 37131086 [TBL] [Abstract][Full Text] [Related]
8. Recalcitrant chylothorax and chylous ascites associated with hypothyroidism. Kollef MH Mil Med; 1993 Jan; 158(1):63-5. PubMed ID: 8437744 [TBL] [Abstract][Full Text] [Related]
9. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032 [TBL] [Abstract][Full Text] [Related]
10. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056 [TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics of systemic lupus erythematosus with chylothorax and/or chylous ascites: An analysis of 15 cases in China. Zhang GH; Zhang LL; Wang YH; Shen WB Medicine (Baltimore); 2020 Dec; 99(51):e23661. PubMed ID: 33371102 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer. Sun F; McCoach CE Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651 [TBL] [Abstract][Full Text] [Related]
16. How we approach pediatric congenital chylous effusions and ascites. Nakano TA; Dori Y; Gumer L; Liptzin DR; Hill LRS; Kulungowski AM Pediatr Blood Cancer; 2022 Aug; 69 Suppl 3():e29246. PubMed ID: 36070215 [TBL] [Abstract][Full Text] [Related]
17. RET fusions in solid tumors. Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421 [TBL] [Abstract][Full Text] [Related]
18. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000 [TBL] [Abstract][Full Text] [Related]
19. Use of Propranolol in the Treatment of Chylous Effusions in Infants. Mitchell K; Weiner A; Ramsay P; Sahni M Pediatrics; 2021 Jul; 148(1):. PubMed ID: 34187907 [TBL] [Abstract][Full Text] [Related]
20. [Medical treatment of chylous effusions in newborn infants. Apropos of 3 cases]. Jernite M; Donato L; Favre R; Haddad J; Esposito M; Messer J Arch Fr Pediatr; 1992 Nov; 49(9):811-4. PubMed ID: 1300971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]